Combination pathogenetic therapy for psoriasis: relief of inflammation and correction of metabolic disorders

DOI: https://doi.org/10.29296/25877305-2019-10-06
Download full text PDF
Issue: 
10
Year: 
2019

Professor A. Piruzyan(2), MD; E. Denisova(1, 2), Candidate of Medical Sciences; E. Dvoryankova(2), MD; M. Denieva(3), Candidate of Medical Sciences; V. Sobolev(2); Professor I. Korsunskaya(1, 2), MD 1-Moscow Research and Practical Center for Dermatovenereology and Cosmetology 2-Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow 3-Republican Dermatovenereology Dispensary, Groznyi

Psoriasis is an autoimmune inflammatory disease that is characterized by a predominant skin lesion and has a complex pathogenesis. The current scientific concept of the pathogenesis of this dermatosis gives pride of place in its development to immune-mediated inflammation, the main mechanism of which is immune cell dysfunction. In addition, systemic and local dyslipidemia can cause inflammation. Immunoinflammatory responses and lipid profile disorders are currently considered as promising therapeutic targets for psoriasis. The authors’ own observations show that the inclusion of drugs that can affect both inflammation and lipid profile (glycyrrhizic acid and essential phospholipids) in the combination therapy of psoriasis makes it possible not only to normalize the blood levels of total cholesterol, triglycerides and other lipids, but also to more quickly get significant regression results in skin rashes.
Keywords: 
dermatology
psoriasis
dyslipidemia
essential phospholipids
glycyrrhizic acid

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Gudjonsson J., Elder J. Psoriasis. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell D, editors. Fitzpatrick’s dermatology in general medicine. 7th ed. Vol. 1 / New York: McGraw-Hill, 2008; pp. 169–93.
  2. Schön M. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders // Front Immunol. – 2019; 10: 1764. DOI: 10.3389/fimmu.2019.01764.
  3. Fuchs J., Zollner T., Kaufmann R. et al. Redox-modulated pathways in inflammatory skin diseases // Free Radic. Biol. Med. – 2001; 30 (4): 337–53.
  4. Trouba K., Hamadeh H., Amin R. et al. Oxidative stress and its role in skin disease // Antioxid. Redox. Signal. – 2002; 4 (4): 665–73.
  5. Davidovici B., Sattar N., Prinz J. et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions // J. Invest. Dermatol. – 2010; 130 (7): 1785–96.
  6. Dvorjankova E.V., Piruzjan A.L., Sobolev V.V. i dr. Problema dislipidemii v dermatologii // Effektivnaja farmakoterapija. – 2018; 21: 14–7 [Dvoryankova Ye.V., Piruzyan A.L., Soboleva A.G. et al. Problem Dislipidemia in Dermatology // Effektivnaya farmakoterapiya. – 2018; 21: 14–7 (in Russ.)].
  7. Johnston A., Arnadottir S., Gudjonsson J. et al. Obesity in psoriasis: Leptin and resistin as mediators of cutaneous inflammation // Br. J. Dermatol. – 2008; 159: 342–50.
  8. Ma C., Harskamp C., Armstrong E. et al. The association between psoriasis and dyslipidaemia: a systematic review // Br. J. Dermatol. – 2013; 168 (3): 486–95. DOI: 10.1111/bjd.12101.
  9. Zykova O.S., Sobolevskaja I.S., Mjadelets O.D. i dr. Morfologicheskie osobennosti raspredelenija svobodnogo holesterola v epidermise pri psoriaze // Vestnik Vitebskogo Gosudarstvennogo Meditsinskogo Universiteta. – 2012; 11 (1): 42–7 [Zykova O.S., Sobolevskaya I.S., Myadelets O.D. et al. Morfologicheskie osobennosti raspredeleniya svobodnogo kholesterola v epidermise pri psoriaze // Vestnik Vitebskogo Gosudarstvennogo Meditsinskogo Universiteta. – 2012; 11 (1): 42–7 (in Russ.)].
  10. Monteiro R., Azevedo I. Chronic inflammation in obesity and the metabolic syndrome // Mediators Inflamm. – 2010; 2010: 289645. DOI: 10.1155/2010/289645.
  11. Korsunskaja I.M., Piruzjan A.L., Sakanija L.R. i dr. Rol' glitsirrizinovoj kisloty v patogeneze psoriaticheskoj bolezni // Effektivnaja farmakoterapija. – 2016; 13: 24–31 [Korsunskaya I.M., Piruzyan A.L., Sakaniya L.R. et al. A Role of Glycyrrhizic Acid in Pathogenesis of Psoriatic Disease // Effektivnaya farmakoterapiya. – 2016; 13: 24–31 (in Russ.)].
  12. Khunger N., Gupta D., Ramesh V. Is psoriasis a new cutaneous marker for metabolic syndrome? A study in Indian patients // Indian J. Dermatol. – 2013; 58: 313–4. DOI: 10.4103/0019-5154.113958.
  13. Greenberg A., Obin M. Obesity and the role of adipose tissue in inflammation and metabolism // Am. J. Clin. Nutr. – 2006; 83 (2): 461S–5S. DOI: 10.1093/ajcn/83.2.461S.
  14. Xu S., Zhang X., Pan M. et al. Treatment of plaque psoriasis with IL-23p19 blockers: A systematic review and meta-analysis // Int. Immunopharmacol. – 2019; 75: 105841. DOI: 10.1016/j.intimp.2019.105841.
  15. Clark C., Taghizadeh M., Nahavandi M. et al. Efficacy of ω-3 supplementation in patients with psoriasis: a meta-analysis of randomized controlled trials // Clin. Rheumatol. – 2019; 38 (4): 977–88. DOI: 10.1007/s10067-019-04456-x.
  16. Zheng Q., Liang S., Xu F. et al. C5a/C5aR1 Pathway Is Critical for the Pathogenesis of Psoriasis // Front Immunol. – 2019; 10: 1866. DOI: 10.3389/fimmu.2019.01866.
  17. Denisova E.V., Dvorjankova E.V., Plieva K.T. i dr. Patologii gepatobiliarnoj sistemy u bol'nyh psoriazom // Effektivnaja farmakoterapija. – 2018; 21: 18–23 [Denisova Ye.V., Dvoryankova Ye.V., Plieva K.T. et al. Pathology of the hepatobiliary system in patients with psoriasis // Effektivnaya farmakoterapiya. – 2018; 21: 18–23 (in Russ.)].
  18. Sahebkar A. Fat lowers fat: purified phospholipids as emerging therapies for dyslipidemia // Biochim. Biophys. Acta. – 2013; 1831 (4): 887–93. DOI: 10.1016/j.bbalip.2013.01.013.
  19. Egeberg A., Andersen Y., Halling-Overgaard A. et al. Systematic Review on Rapidity of Onset of Action for Interleukin-17 and Interleukin-23 Inhibitors for Psoriasis // J. Eur. Acad. Dermatol. Venereol. – 2019. DOI: 10.1111/jdv.15920